ReviewBritish journal of cancer2004
First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
Review in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- The efficacy of gefitinib supplementation for breast cancer: A meta-analysis of randomized controlled studies.Medicine · 2020Pooled it
- Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.British journal of clinical pharmacology · 2016Trial
- Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial.British journal of cancer · 2009Trial
- Comparative efficacy of Palbociclib and Everolimus with aromatase inhibitors in second line treatment of HR and HER2 negative metastatic breast cancer.Discover oncology · 2025Article
- Comparison of the effects of crizotinib as monotherapy and as combination therapy with butyric acid on different breast cancer cells.Oncology letters · 2025Article
- Article
- Chemoprevention of LA7-Induced Mammary Tumor Growth by SM6Met, a Well-CharacterizedFrontiers in pharmacology · 2018Article
- Article
- What is known about melatonin, chemotherapy and altered gene expression in breast cancer.Oncology letters · 2017Article
- Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.Cell cycle (Georgetown, Tex.) · 2016Article
- Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells.Biochemical and biophysical research communications · 2015Article
- Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.Journal of ovarian research · 2014Article
- A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.PloS one · 2014Article
- The antiestrogen 4-hydroxytamoxifen protects against isotretinoin-induced permeability transition and bioenergetic dysfunction of liver mitochondria: comparison with tamoxifen.Journal of bioenergetics and biomembranes · 2013Article
- Review
- Article
- Characterization of aromatase binding agents from the dichloromethane extract of Corydalis yanhusuo using ultrafiltration and liquid chromatography tandem mass spectrometry.Molecules (Basel, Switzerland) · 2010Article
- Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells.British journal of cancer · 2009Article
- Genotype-guided tamoxifen therapy: time to pause for reflection?The Lancet. Oncology · 2009Review
- Natural products as aromatase inhibitors.Anti-cancer agents in medicinal chemistry · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until recently, endocrine therapy for breast cancer was relatively simple. If the tumour expressed hormone receptors, regardless of stage and age, tamoxifen was indicated. While this largely remains the case for premenopausal women, clinical trials in postmenopausal women have broadened our choice to include one of three selective aromatase inhibitors (AIs), the nonsteroidal agents anastrozole or letrozole and the steroidal agent exemestane. Comparative data concerning the efficacy, toxicity, tolerability and cost of AI vs tamoxifen continues to evolve with over 40 000 women slated to be involved in clinical trials. Currently, tamoxifen remains an appropriate choice for adjuvant treatment, and will remain so unless a clear survival advantage emerges for adjuvant AI therapy. However, anastrozole is widely seen as a useful alternative, with particular merit for patients prone to the development of serious tamoxifen side effects. For endocrine therapy naïve advanced disease, several trials have provided evidence that a nonsteroidal AI has replaced tamoxifen as optimal treatment. In the neoadjuvant setting, letrozole was also more effective than tamoxifen, both in terms of response rates and the incidence of breast-conserving surgery, and so AI therefore also dominates this evolving indication. The ongoing adjuvant clinical trials ask all the relevant questions regarding tamoxifen and AI in combination, sequence and duration, except for 5 years of an AI vs a longer period. For both the advanced and early-stage disease, resistance remains the key obstacle to overcome, and trials that combine endocrine agents with signal transduction inhibitors such as HER1 and HER2 kinase inhibitors, farnesyl transferase inhibitors, mTOR inhibitors as well as COX2 inhibitors are being developed in a concerted attempt to address this problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.